CSIMarket
 


Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 

Cumulative Kalvista Pharmaceuticals Inc 's Leverage Ratio for Trailing Twelve Months Period

KALV's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

KALV Leverage Ratio for Trailing Twelve Months Period

(Oct 31 2023)
II. Quarter
(Jul 31 2023)
I. Quarter
(Apr 30 2023)
IV. Quarter
(Jan 31 2023)
III. Quarter
(Oct 31 2022)
II. Quarter
Y / Y Equity Growth -20.42 % -15.33 % -13 % -11.3 % -36.78 %
Y / Y Total Liabilities Growth 61.29 % 48.92 % 31.57 % 22.17 % 12.09 %
Leverage Ratio for Trailing Twelve Months Period 0.09 0.08 0.07 0.06 0.05
Total Ranking # 276 # 267 # 264 # 275 # 274
Seq. Equity Growth -17.86 % -13.47 % -12.7 % 28.25 % -12.61 %
Seq. Total Liabilities Growth 27.62 % -6.7 % 32.19 % 2.48 % 17.83 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Oct 31 2023
On the trailing twelve months basis Due to net new borrowings of 27.62%, Leverage Ratio for Trailing Twelve Months Period improved to 0.09, below Kalvista Pharmaceuticals Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 104 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Kalvista Pharmaceuticals Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are KALV's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 105
Sector # 152
S&P 500 # 276


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.95 0.24 0.07
(Jul 31 2018)   (Jan 31 2022)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Oct 31 2023, within Major Pharmaceutical Preparations Industry Leverage Ratio for Trailing Twelve Months Period
Akouos inc   0.25 
Allakos Inc   0.25 
Vascular Biogenics Ltd   0.24 
Kronos Bio Inc   0.24 
Annexon Inc   0.24 
Lumos Pharma Inc   0.24 
United Therapeutics Corporation  0.24 
Zynerba Pharmaceuticals Inc   0.24 
Lianbio  0.24 
Dyne Therapeutics Inc   0.23 
Clever Leaves Holdings Inc   0.23 
Regeneron Pharmaceuticals Inc   0.23 
Erasca Inc   0.23 
Galmed Pharmaceuticals Ltd   0.23 
Neurogene Inc   0.23 
Affimed N v   0.23 
Lipella Pharmaceuticals Inc   0.23 
Galecto Inc   0.23 
Sanofi  0.22 
Histogen Inc   0.22 
Ligand Pharmaceuticals Incorporated  0.22 
Lftd Partners Inc   0.22 
Deciphera Pharmaceuticals Inc   0.21 
Xilio Therapeutics inc   0.21 
Bio path Holdings inc   0.21 
Assembly Biosciences Inc   0.21 
Phio Pharmaceuticals Corp   0.21 
Oramed Pharmaceuticals Inc   0.21 
Catalyst Pharmaceuticals Inc   0.21 
Matinas Biopharma Holdings Inc   0.21 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com